Clorox (NYSE:CLX) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

CLX has been the subject of a number of other research reports. Bank of America increased their price target on Clorox from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Monday, July 16th. UBS Group initiated coverage on Clorox in a research note on Wednesday, July 18th. They issued a “sell” rating and a $110.00 price target for the company. Atlantic Securities initiated coverage on shares of Clorox in a report on Thursday. They set a “neutral” rating and a $151.00 price objective for the company. Goldman Sachs Group downgraded shares of Clorox from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $127.00 to $112.00 in a report on Tuesday, July 17th. They noted that the move was a valuation call. Finally, BMO Capital Markets reissued a “buy” rating and set a $153.00 price objective on shares of Clorox in a report on Friday, August 3rd. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $131.79.

Shares of CLX stock opened at $152.47 on Friday. Clorox has a 52-week low of $113.57 and a 52-week high of $153.38. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 3.15. The firm has a market capitalization of $19.53 billion, a price-to-earnings ratio of 24.36, a price-to-earnings-growth ratio of 3.16 and a beta of 0.35.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $1.66 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.58 by $0.08. Clorox had a return on equity of 103.18% and a net margin of 13.44%. The business had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.72 billion. During the same quarter in the prior year, the business posted $1.53 EPS. Clorox’s revenue for the quarter was up 2.7% compared to the same quarter last year. analysts expect that Clorox will post 6.41 EPS for the current year.

In related news, EVP Jon M. Balousek sold 3,354 shares of the stock in a transaction dated Wednesday, August 29th. The shares were sold at an average price of $144.73, for a total value of $485,424.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael R. Costello sold 9,265 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $140.02, for a total transaction of $1,297,285.30. Following the completion of the transaction, the senior vice president now directly owns 34,293 shares of the company’s stock, valued at approximately $4,801,705.86. The disclosure for this sale can be found here. Insiders have sold a total of 29,268 shares of company stock valued at $4,196,686 in the last three months. Insiders own 1.00% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Carillon Tower Advisers Inc. lifted its holdings in shares of Clorox by 82.8% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 109,150 shares of the company’s stock valued at $14,763,000 after acquiring an additional 49,450 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Clorox by 0.4% in the 2nd quarter. Victory Capital Management Inc. now owns 105,329 shares of the company’s stock valued at $14,246,000 after acquiring an additional 456 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Clorox by 7.2% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 63,730 shares of the company’s stock valued at $8,620,000 after acquiring an additional 4,281 shares during the last quarter. Homrich & Berg lifted its holdings in shares of Clorox by 6.5% in the 2nd quarter. Homrich & Berg now owns 9,021 shares of the company’s stock valued at $1,220,000 after acquiring an additional 552 shares during the last quarter. Finally, Unigestion Holding SA bought a new position in shares of Clorox in the 2nd quarter valued at about $73,819,000. 78.08% of the stock is owned by hedge funds and other institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Featured Article: What Does Beta Mean In Stock Selection

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.